BP
ALXN

Banyan Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Banyan Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2.02M Sell
12,149
-945
-7% -$155K 0.17% 144
2014
Q2 		$2.05M Sell
13,094
-1,535
-10% -$242K 0.17% 148
2014
Q1 		$2.23M Sell
14,629
-37
-0.3% -$5.88K 0.19% 137
2013
Q4 		$1.95M Buy
+14,666
New +$1.76M 0.14% 163

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Banyan Partners's ALXN Position: Q3 2014 in Review

Banyan Partners reduced its Alexion Pharmaceuticals (ALXN) stake by 7.2% in Q3 2014, selling an estimated $155K and leaving 12,149 shares worth $2.02M. The position accounts for 0.17% of the portfolio, ranked #144.

Banyan Partners first reported a position in ALXN in Q4 2013 and has held it in 4 quarters since. The position peaked at $2.23M in Q1 2014. 522 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

  • Banyan Partners held 12,149 shares of Alexion Pharmaceuticals worth $2.02M as of Q3 2014.
  • Banyan Partners sold 945 Alexion Pharmaceuticals shares in Q3 2014, an estimated $155K.
  • Alexion Pharmaceuticals made up 0.17% of Banyan Partners's portfolio in Q3 2014, its #144 holding.
  • Banyan Partners first reported a position in Alexion Pharmaceuticals in Q4 2013 and has held it in 4 quarters since.
  • Banyan Partners's Alexion Pharmaceuticals position peaked at $2.23M in Q1 2014.
  • 522 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on Banyan Partners's 13F filing for Q3 2014, filed 14 Nov 2014.